Ashley Cox
Partner, Head of Europe
Expertise:
Ashley comes to EVERSANA as パートナー, Head of Europe, from SmartAnalyst where she was Head of European Business Development. In this role, she led business development activities across Europe, with a focus on developing disease, asset, and portfolio strategies at the earlier stages of clinical development. Prior to SmartAnalyst, Ashley was Vice President at PharmaVentures, Ltd., a boutique corporate advisory firm that represents mostly sell-side opportunities for both partnering and divestment to global and regional pharmaceutical organizations. There, she was responsible for leading cross-functional teams to deliver valuations, lead transaction activities, and develop a new strategic consulting vertical.
Earlier in her career, Ashley was Head of Global Business Development for the Prescient Healthcare Group, with a strong focus on Competitive Intelligence and Business Analytics. Ashley has supported decision-making across the majority of the top 20 pharma and many biotech companies. She started her career as a Medical Representative and has held a variety of commercial and licensing roles across the pharmaceutical and generics sectors.
Ashley is the President of the London Chapter of the Healthcare Businesswomen’s Association (HBA), an organisation striving for gender parity, diversity, equity and inclusion. Ashley is ABPI qualified and holds an MSc. in Pharmaceutical Analysis from the University of Strathclyde and a BSC. (Hons) in Neuroscience from the University of Glasgow.
Articles by Ashley Cox
Unlocking Success: Exploring Critical Factors for Launching Orphan Drugs
A Conversation with Ashley Cox, Senior Principal, Head of Europe, EVERSANA MANAGEMENT CONSULTING, and Sid Agrawal, Senior Principal, EVERSANA MANAGEMENT CONSULTING Join Ashley Cox, Senior Principal and Head of Europe, and Sid Agrawal, Senior Principal, as they delve into the realm of orphan drugs. With 6,424 designations granted since 1983 and 1,085 products receiving FDA marketing approval, the pharmaceutical marketplace has witnessed a significant presence of these unique medications. The average time for designation to approval stands at 5.3 years, and the number of designations has quadrupled from the 1990s to the 2010s. Notably, oncology, neurology, and infectious disease account for over half of all orphan drug designations. While the […]
Successfully Navigating Self-Commercialisation in Europe
Introduction As discussed in our previous paper, Successful Launches in Europe: Complex, But Not Complicated?,, Europe is one of the world’s largest and most important regions of focus for pharmaceutical and biotechnology manufacturers looking to treat patients and maximise the value of their products. However, the challenges of entering this market, particularly in terms of its complexity, can be intimidating and may deter some companies from launching themselves. Companies may prefer to out-license or sign agreements with distributors, which are the more traditional routes to market. However, these agreements result in less control for the manufacturer regarding all aspects of the launch strategy and decreased long-term company awareness and revenue […]
Successful Launches in Europe: Complex, but Not Complicated?
Europe represents a major pharmaceutical market – it accounts for 22% of the global market, second only to the U.S. in terms of market size and has a large population of over 500 million. Understandably, pharmaceutical and biotechnology companies looking to maximise their revenue consider Europe to be a key focus[1]. Indeed, looking at first-time drug launches by biotech companies, between 2010 and 2020, two-thirds of U.S. launches were followed by launches in other countries[2]. Our paper, “Successful Launches in Europe: Complex but Not Complicated,” discusses the challenges and opportunities associated with launching a pharmaceutical product in Europe. This paper emphasizes the need for pharmaceutical companies to adopt a comprehensive […]